Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RARX

Ra Pharmaceuticals (RARX) Stock Price, News & Analysis

Ra Pharmaceuticals logo

About Ra Pharmaceuticals Stock (NASDAQ:RARX)

Advanced Chart

Key Stats

Today's Range
$47.99
$47.99
50-Day Range
$47.99
$48.00
52-Week Range
$19.64
$48.02
Volume
30,200 shs
Average Volume
1.16 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RARX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RARX Stock News Headlines

RA: Discount Continues To Leave Some Opportunity
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
RARX_old Historical Data
See More Headlines

RARX Stock Analysis - Frequently Asked Questions

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings data on Thursday, February, 27th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.16.

Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Verastem (VSTM), Amarin (AMRN), Bausch Health Cos (BHC) and Galmed Pharmaceuticals (GLMD).

Company Calendar

Last Earnings
2/27/2020
Today
7/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RARX
CIK
1481512
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$102.69 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.61%
Return on Assets
-41.60%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
14.78
Quick Ratio
14.79

Sales & Book Value

Annual Sales
$3 million
Price / Sales
757.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.56 per share
Price / Book
8.63

Miscellaneous

Outstanding Shares
47,329,000
Free Float
N/A
Market Cap
$2.27 billion
Optionable
Optionable
Beta
1.05
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:RARX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners